PFM Health Sciences, LP
13F filer · CIK 0001442756Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$1.17BU.S. long equity reported on 13F
Positions9632 new · 12 closed
Net flow last quarter-$2.1MBuys minus sells
Top 10 positions weight33.9%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202696 positions | |||||
| $62.2M | 5.34% | 0.38% | +53.4% | Q4 2018 | |
| $53.8M | 4.61% | 0.42% | -16.9% | Q2 2022 | |
| $47.1M | 4.04% | 0.00% | -40.3% | Q3 2015 | |
| $38.7M | 3.32% | 0.26% | -9.8% | Q1 2015 | |
| $37.5M | 3.22% | 0.08% | Not reported | Q3 2013 | |
| $36.7M | 3.15% | 0.01% | +52.1% | Q4 2014 | |
| $36M | 3.09% | 0.21% | -1.1% | Q1 2021 | |
| $29.2M | 2.51% | 2.10% | +1.0% | Q1 2023 | |
| $27.1M | 2.32% | 0.12% | +25.6% | Q4 2024 | |
| $26.8M | 2.30% | 0.07% | +1.7% | Q3 2020 | |
| $23.7M | 2.03% | 0.18% | +137.4% | Q3 2016 | |
| $23.7M | 2.03% | 0.15% | -68.2% | Q3 2013 | |
| $22.7M | 1.94% | 0.04% | -1.6% | Q4 2014 | |
| $22.4M | 1.93% | 0.06% | +50.5% | Q2 2013 | |
| $19M | 1.63% | 0.15% | -56.9% | Q3 2015 | |
| $18.9M | 1.62% | 0.13% | -1.7% | Q4 2024 | |
| $17.8M | 1.53% | 0.01% | +158.0% | Q4 2014 | |
| $17M | 1.46% | 0.07% | Not reported | Q4 2016 | |
| $16.5M | 1.41% | 0.33% | -30.2% | Q1 2025 | |
| $16.3M | 1.40% | 0.01% | Not reported | Q2 2013 | |
| $16.3M | 1.40% | 0.15% | Not reported | Q4 2020 | |
| $16.2M | 1.39% | 0.22% | Not reported | Q3 2023 | |
| $16M | 1.37% | 0.05% | -5.6% | Q3 2014 | |
| $15.8M | 1.36% | 0.11% | +30.1% | Q2 2013 | |
| $15.7M | 1.35% | 0.13% | -14.2% | Q1 2021 | |
| $15.5M | 1.33% | 0.58% | -9.9% | Q2 2015 | |
| $15.1M | 1.30% | 0.26% | -8.8% | Q1 2026 | |
| $14.8M | 1.27% | Not reported | +3.8% | Q2 2023 | |
| $14.3M | 1.23% | 0.01% | +92.1% | Q2 2013 | |
| $14.2M | 1.22% | 0.01% | Not reported | Q1 2025 | |
| $13.7M | 1.17% | 0.33% | +21.3% | Q2 2017 | |
| $12.9M | 1.11% | 0.14% | +8.9% | Q2 2021 | |
| $12.8M | 1.09% | 0.44% | +5.5% | Q4 2023 | |
| $12.7M | 1.09% | Not reported | +34.4% | Q1 2026 | |
| $11.8M | 1.02% | 0.37% | -6.2% | Q4 2025 | |
| $11.8M | 1.01% | 0.22% | -29.6% | Q3 2025 | |
| $11.7M | 1.01% | 0.19% | +21.3% | Q1 2026 | |
| $11.5M | 0.98% | 0.01% | Not reported | Q1 2013 | |
| $11.3M | 0.97% | 0.15% | -25.7% | Q3 2025 | |
| $11.2M | 0.96% | 0.12% | -12.2% | Q3 2020 | |
| $10.7M | 0.92% | 0.09% | +104.8% | Q1 2026 | |
| $10.2M | 0.87% | 0.19% | -19.7% | Q1 2026 | |
| $10.1M | 0.87% | 0.18% | Not reported | Q1 2018 | |
| $9.96M | 0.85% | 0.22% | -3.0% | Q1 2024 | |
| $9.9M | 0.85% | 0.07% | -24.3% | Q4 2025 | |
| $9.62M | 0.83% | 0.31% | +28.3% | Q3 2025 | |
| $9.48M | 0.81% | 0.04% | +29.2% | Q2 2023 | |
| $9.11M | 0.78% | 0.15% | -22.7% | Q3 2025 | |
| $8.32M | 0.71% | 0.15% | -48.3% | Q3 2025 | |
| $8M | 0.69% | 2.33% | +123.8% | Q1 2026 | |
| Q1 2026Reported May 15, 202676 positions | |||||
| $75.2M | 6.86% | 0.46% | +0.2% | Q3 2013 | |
| $60.5M | 5.52% | 0.01% | -3.7% | Q3 2015 | |
| $45.9M | 4.19% | 0.36% | -3.7% | Q3 2015 | |
| $44.7M | 4.07% | 0.51% | +5.1% | Q2 2022 | |
| $34.8M | 3.17% | 0.25% | -14.4% | Q4 2018 | |
| $33.7M | 3.07% | 0.29% | +252.7% | Q1 2015 | |
| $28.4M | 2.59% | 0.21% | +32.2% | Q1 2021 | |
| $23.6M | 2.15% | 0.09% | -41.2% | Q4 2024 | |
| $23.2M | 2.12% | 0.37% | +7.0% | Q4 2025 | |
| CPCNTACentessa Pharmaceuticals PLC | $21M | 1.91% | 0.34% | -10.7% | Q1 2024 |
| $20.5M | 1.87% | 2.09% | +15.0% | Q1 2023 | |
| $20.4M | 1.86% | 0.04% | +3.1% | Q4 2014 | |
| $19.1M | 1.75% | 0.13% | -15.9% | Q4 2024 | |
| $17.9M | 1.63% | 0.15% | +370.5% | Q1 2021 | |
| $17.5M | 1.60% | 0.46% | +59.3% | Q1 2025 | |
| $15.7M | 1.43% | 0.01% | +14.8% | Q4 2014 | |
| $14.4M | 1.32% | 0.32% | +72.9% | Q3 2025 | |
| $14.4M | 1.31% | 0.01% | Not reported | Q2 2017 | |
| $13.7M | 1.25% | 0.07% | -7.1% | Q3 2020 | |
| $13.6M | 1.24% | 0.64% | Not reported | Q2 2015 | |
| $13.2M | 1.21% | 1.38% | +5.3% | Q1 2025 | |
| $12.1M | 1.11% | 0.09% | +68.5% | Q2 2013 | |
| $12M | 1.09% | 0.04% | Not reported | Q2 2025 | |
| $11.9M | 1.08% | 0.39% | +26.7% | Q4 2025 | |
| $11.9M | 1.08% | 0.20% | +239.8% | Q3 2025 | |
| $11.8M | 1.08% | 0.04% | -8.0% | Q2 2013 | |
| $11.6M | 1.05% | 0.30% | -36.5% | Q3 2025 | |
| $11.4M | 1.04% | 0.13% | +13.7% | Q2 2021 | |
| $11.3M | 1.03% | 0.13% | Not reported | Q3 2020 | |
| $11.2M | 1.02% | 0.19% | +1.2% | Q3 2025 | |
| $11.2M | 1.02% | 0.27% | Not reported | Q2 2017 | |
| $10.3M | 0.94% | 0.49% | +144.0% | Q4 2023 | |
| $9.48M | 0.86% | 0.15% | +199.8% | Q4 2025 | |
| $9.4M | 0.86% | 0.04% | -34.1% | Q4 2015 | |
| TPTERNTerns Pharmaceuticals, Inc. | $9.12M | 0.83% | 0.15% | Not reported | Q1 2021 |
| $8.63M | 0.79% | 0.05% | -63.7% | Q3 2014 | |
| $8.56M | 0.78% | 0.23% | +39.2% | Q1 2024 | |
| $8.54M | 0.78% | 0.35% | New | Q1 2026 | |
| $8.5M | 0.77% | 0.28% | New | Q1 2026 | |
| STSLNOSoleno Therapeutics Inc | $8.31M | 0.76% | 0.48% | +0.1% | Q4 2024 |
| $7.98M | 0.73% | 0.10% | +58.1% | Q4 2025 | |
| $7.56M | 0.69% | 1.01% | +75.4% | Q2 2022 | |
| $7.29M | 0.66% | 0.00% | -60.9% | Q2 2013 | |
| $7.25M | 0.66% | Not reported | New | Q1 2026 | |
| $7.21M | 0.66% | 0.01% | -56.8% | Q4 2014 | |
| $7.03M | 0.64% | 0.27% | +62.4% | Q3 2025 | |
| $6.95M | 0.63% | 0.79% | +0.6% | Q4 2025 | |
| $6.75M | 0.62% | 0.01% | -48.8% | Q3 2014 | |
| $6.36M | 0.58% | 0.08% | -50.2% | Q3 2016 | |
| $6.34M | 0.58% | 0.17% | New | Q1 2026 | |
| Q4 2025Reported Feb 17, 202676 positions | |||||
| $79M | 7.88% | 0.45% | -13.8% | Q3 2013 | |
| $73.4M | 7.32% | 0.01% | -69.7% | Q3 2015 | |
| $45.9M | 4.58% | 0.49% | -52.6% | Q2 2022 | |
| $45.1M | 4.50% | 0.37% | -25.6% | Q3 2015 | |
| $37.9M | 3.78% | 0.29% | +22.3% | Q4 2018 | |
| $33M | 3.29% | 0.16% | -29.2% | Q4 2024 | |
| $29.9M | 2.98% | 0.15% | +26.3% | Q3 2014 | |
| $23.4M | 2.34% | 0.16% | -6.3% | Q4 2024 | |
| $23.2M | 2.31% | 0.53% | +7.6% | Q3 2025 | |
| $23.1M | 2.31% | 0.16% | +185.1% | Q1 2021 | |
| $22.8M | 2.27% | 0.35% | New | Q4 2025 | |
| $22M | 2.19% | 0.01% | +1538.5% | Q2 2013 | |
| $21M | 2.10% | 0.04% | -35.3% | Q4 2014 | |
| $21M | 2.10% | 0.15% | -13.7% | Q3 2016 | |
| $21M | 2.09% | 1.82% | +10.8% | Q1 2023 | |
| $20.5M | 2.05% | 0.02% | New | Q4 2025 | |
| $19.9M | 1.99% | 1.31% | -23.3% | Q1 2025 | |
| $19.8M | 1.97% | 0.01% | -20.6% | Q2 2013 | |
| $18.5M | 1.84% | 0.47% | +311.9% | Q3 2025 | |
| $17.9M | 1.78% | 0.01% | Not reported | Q4 2014 | |
| $16.7M | 1.66% | 0.01% | Not reported | Q4 2014 | |
| $16.4M | 1.64% | 0.07% | +40.5% | Q2 2013 | |
| $15.1M | 1.50% | 0.06% | Not reported | Q4 2015 | |
| CPCNTACentessa Pharmaceuticals PLC | $14.8M | 1.48% | 0.40% | -11.2% | Q1 2024 |
| $12.9M | 1.29% | 0.29% | -35.8% | Q1 2025 | |
| $12.8M | 1.28% | 0.03% | Not reported | Q3 2014 | |
| $12.5M | 1.25% | Not reported | -50.6% | Q1 2013 | |
| $12.5M | 1.25% | 0.23% | Not reported | Q1 2018 | |
| $12.1M | 1.20% | 0.08% | -54.3% | Q3 2020 | |
| STSLNOSoleno Therapeutics Inc | $11.5M | 1.14% | 0.47% | +1.9% | Q4 2024 |
| $9.18M | 0.92% | 0.12% | -48.6% | Q2 2021 | |
| $8.73M | 0.87% | 0.00% | -80.1% | Q2 2018 | |
| $8.72M | 0.87% | 0.01% | Not reported | Q1 2013 | |
| $8.59M | 0.86% | 0.08% | Not reported | Q1 2015 | |
| $8.55M | 0.85% | 0.01% | -68.9% | Q1 2025 | |
| $8.55M | 0.85% | 0.01% | New | Q4 2025 | |
| $8.53M | 0.85% | 0.02% | Not reported | Q1 2019 | |
| $8.36M | 0.83% | 0.31% | New | Q4 2025 | |
| $8.26M | 0.82% | 0.05% | +35.6% | Q2 2013 | |
| $7.25M | 0.72% | 0.02% | -21.7% | Q2 2022 | |
| $7.18M | 0.72% | Not reported | -39.1% | Q2 2023 | |
| $7.16M | 0.71% | 0.78% | New | Q4 2025 | |
| $6.81M | 0.68% | 0.20% | +3.9% | Q3 2025 | |
| $6.65M | 0.66% | 0.16% | +3.0% | Q1 2024 | |
| $6.61M | 0.66% | 0.06% | Not reported | Q1 2013 | |
| $6.47M | 0.65% | 0.01% | -78.9% | Q1 2013 | |
| $6.41M | 0.64% | 0.79% | New | Q4 2025 | |
| $5.45M | 0.54% | 0.17% | -79.0% | Q3 2025 | |
| $5.38M | 0.54% | 0.81% | -53.1% | Q2 2022 | |
| $5.1M | 0.51% | 0.28% | -5.3% | Q1 2021 | |
| Q3 2025Reported Nov 14, 202566 positions | |||||
| $172M | 13.21% | 0.02% | -16.0% | Q3 2015 | |
| $93.7M | 7.21% | 0.52% | -7.5% | Q3 2013 | |
| $64.4M | 4.95% | 1.05% | +9.8% | Q2 2022 | |
| $55.9M | 4.30% | 0.06% | Not reported | Q3 2013 | |
| $49.4M | 3.80% | 0.50% | +17.3% | Q3 2015 | |
| $40.1M | 3.08% | 0.22% | +162.8% | Q4 2024 | |
| $34.6M | 2.66% | 0.02% | -13.0% | Q2 2018 | |
| $29.7M | 2.28% | 0.07% | -2.9% | Q4 2014 | |
| $28.9M | 2.22% | 0.24% | -34.5% | Q4 2018 | |
| $28M | 2.16% | 0.03% | -9.0% | Q1 2013 | |
| $26.1M | 2.01% | 0.03% | -27.6% | Q1 2025 | |
| $25.2M | 1.93% | 0.04% | +51.1% | Q1 2020 | |
| $24.4M | 1.88% | 9.71% | +3.9% | Q3 2020 | |
| $23.8M | 1.83% | Not reported | Not reported | Q1 2013 | |
| $23.4M | 1.80% | 0.18% | +51.6% | Q3 2016 | |
| $20.5M | 1.58% | 0.12% | Not reported | Q3 2014 | |
| $19.8M | 1.53% | 0.01% | Not reported | Q2 2013 | |
| $19.6M | 1.51% | 0.03% | Not reported | Q2 2015 | |
| $18.6M | 1.43% | 0.08% | +14.2% | Q2 2025 | |
| $17.3M | 1.33% | 0.50% | New | Q3 2025 | |
| $17M | 1.31% | 1.71% | +186.8% | Q1 2025 | |
| $17M | 1.31% | 0.17% | -37.3% | Q4 2024 | |
| STSLNOSoleno Therapeutics Inc | $16.5M | 1.27% | 0.45% | -40.2% | Q4 2024 |
| CPCNTACentessa Pharmaceuticals PLC | $16.2M | 1.24% | 0.50% | +93.1% | Q1 2024 |
| $15.5M | 1.19% | Not reported | +11.7% | Q2 2023 | |
| $15.5M | 1.19% | 0.17% | Not reported | Q3 2020 | |
| $14.9M | 1.15% | 0.80% | New | Q3 2025 | |
| $14.1M | 1.09% | Not reported | +23.8% | Q3 2017 | |
| $13.5M | 1.04% | 0.45% | -58.6% | Q1 2025 | |
| $12.4M | 0.95% | 0.03% | Not reported | Q2 2022 | |
| MMRUSMerus N.V. | $12.3M | 0.95% | 0.17% | -28.9% | Q2 2025 |
| ATAKROAkero Therapeutics, Inc. | $11.8M | 0.91% | 0.31% | -6.8% | Q3 2023 |
| $11.2M | 0.86% | 0.02% | Not reported | Q1 2013 | |
| $11.2M | 0.86% | 0.20% | -26.3% | Q2 2018 | |
| $9.53M | 0.73% | 1.73% | -6.5% | Q2 2022 | |
| $9.22M | 0.71% | 0.05% | -28.6% | Q2 2013 | |
| VPVRNAVerona Pharma plc | $8.58M | 0.66% | 0.01% | Not reported | Q2 2025 |
| $8.07M | 0.62% | 1.65% | -1.9% | Q1 2023 | |
| $8.04M | 0.62% | 0.06% | +346.5% | Q1 2021 | |
| $7.21M | 0.55% | 0.03% | -71.2% | Q1 2014 | |
| $6.79M | 0.52% | 0.30% | -61.0% | Q2 2025 | |
| $6.36M | 0.49% | 0.20% | New | Q3 2025 | |
| $5.93M | 0.46% | 0.40% | -40.4% | Q1 2025 | |
| $5.1M | 0.39% | 0.04% | Not reported | Q2 2013 | |
| $4.86M | 0.37% | 0.07% | New | Q3 2025 | |
| $4.82M | 0.37% | 0.16% | +386.5% | Q1 2024 | |
| $4.82M | 0.37% | 0.03% | Not reported | Q1 2024 | |
| $4.74M | 0.36% | Not reported | Not reported | Q2 2020 | |
| $4.72M | 0.36% | 0.01% | -11.5% | Q4 2018 | |
| $4.26M | 0.33% | 0.50% | +4.3% | Q2 2025 | |
Premium opens every quarter this fund has filed